HR Execs on the Move

Repligen Corp

www.repligen.com

 
Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor products, which are used to increase cell growth and productivity during upstream fermentation. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality test kits. Further, it has a portfolio of therapeutic product candidates, ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.repligen.com
  • 41 Seyon St Ste 100
    Waltham, MA USA 02453
  • Phone: 781.250.0111

Executives

Name Title Contact Details
Olivier Loeillot
President and Chief Commercial Officer Profile
Travis Harkness
Vice President Supply Chain and Analytics Profile
Travis Ward
Director of R&D Profile
Derek Carroll
Director of R&D Profile
Christine Gebski
Vice President, Product Management and Field Applications Profile

Similar Companies

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stratos Genomics

Stratos Group is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development. Stratos Product Development is a world leader in innovation and high tech product development services.

Ventana Clinical Research Corp

Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BlueSphere Bio

Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…

Rosetta Genomics

Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.   Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.   Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.